TY - JOUR
T1 - Targeting RET-driven cancers
T2 - lessons from evolving preclinical and clinical landscapes
AU - Drilon, Alexander
AU - Hu, Zishuo I.
AU - Lai, Gillianne G.Y.
AU - Tan, Daniel S.W.
PY - 2018/3
Y1 - 2018/3
N2 - Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.175 (2017) In the online and PDF versions of this Review, in the ‘Acquired resistance’ subsection, RETI788N was erroneously written as RETI887N, and the ROS1G2032R mutation was written as ROS1D2033N. This information has now been corrected in the online and PDF versions of the Review.
AB - Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.175 (2017) In the online and PDF versions of this Review, in the ‘Acquired resistance’ subsection, RETI788N was erroneously written as RETI887N, and the ROS1G2032R mutation was written as ROS1D2033N. This information has now been corrected in the online and PDF versions of the Review.
UR - http://www.scopus.com/inward/record.url?scp=85066272895&partnerID=8YFLogxK
U2 - 10.1038/NRCLINONC.2017.188
DO - 10.1038/NRCLINONC.2017.188
M3 - Comment/debate
C2 - 29182164
AN - SCOPUS:85066272895
SN - 1759-4774
VL - 15
SP - 150
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 3
ER -